Horn & Co. Law Offices

Hi-Tech, M&A, IP, Securities Law

Profile Icon

Company's Profile

Established: 2009
Line of Business: Hi-Tech, M&A, IP, Securities Law
Address: 2 Weizmann St., Amot Investments Tower
24 floor, Tel Aviv 6423902
Phone: 972-3-637-8200
Fax: 972-3-637-8201
Email: office@hornlaw.co.il
Website: http://www.hornlaw.co.il
Linkedin: Click to View
Management Icon

Company Executives

  • Yuval Horn, Horn & Co. Law Offices

    Yuval Horn

    Founding Partner

    Horn & Co. Law Offices

    View Profile

    Yuval Horn

Partners

    Keren Kanir
    Roy Ribon
    Ohad Mamann
    Orly Sternfeld
    Paz Abercohen
Icon About

About Horn & Co. Law Offices

Horn & Co. is the leading Israeli boutique law firm in the field of hi-tech and life sciences, and is unique in its exclusive practice and expertise in this field. The firm’s founder, Yuval Horn, was recognized by the International Who’s Who of Life Sciences Lawyers as one of the five leading individuals in the world in life sciences transactions in 2013, 2015 and in 2018.
Horn & Co.’s expertise includes the representation of clients in all aspects of their operations, including especially their technology and intellectual property transactions, their corporate and funding matters and their commercial contracting.
Horn & Co. was founded in September 2009 and is known for its tailored, innovative structures, solutions and advice in complex transactions and situations. Since 1993, both Yuval and his colleagues have represented numerous founders, companies and investors in their transactions in the life science and technology sectors. Recent examples include the representation of IOptima Ltd. and its shareholders in a multi-stage acquisition transaction with an aggregate deal value of up to approximately $50 million, with Chengdu Kanghong Pharmaceutical Group; representation of Eloxx Pharmaceuticals Ltd. in a $38 million financing round and simultaneous entering into a merger agreement; the formation of Pontifax 5 L.P., the fifth fund of Pontifax Venture Capital group, Israel’s most prominent life sciences designated investment fund; and the representation of INX Ltd. in the submission to the SEC of the first prospectus covering security tokens.
Horn & Co. is the Israeli member of Biolegis (www.biolegis.com), a network of leading European law firms with specific expertise in the representation of biotechnology and medical device companies.
The firm’s partners and associates have been recognized by the leading international publications and peers as experts in corporate law, intellectual property and technology transactions and are typically asked to lecture and write about these areas. Horn & Co. has been recognized by Legal 500 as a “Tier 1” firm in Israel in the field of Healthcare and Life Sciences noting that: “the firm has been active at the ‘top level’ in the healthcare sector for over 20 years”.
Yuval has been recognized as an expert in life sciences by the International Who’s Who Legal: Life Sciences and by Legal 500. Since 2008, he has been a member and legal advisor of the Institutional Review Board of the Chaim Sheba Medical Center at Tel-Hashomer. Yuval served as the Co-Chair of the International Bar Association (IBA) Technology Law Committee (2016-2017), is a member of the Executive Committee of the IBA Annual World Life Sciences Conference and a co-organizer of the IBA Annual M&A in the Technology sector conference.

Corporate

Horn & Co. has vast experience in the representation of biotechnology, medical device, software, telecommunications and cleantech companies. Its corporate clients include companies of all sizes, from Israeli based incubator companies to multinational companies conducting business in Israel.

Intellectual Property Transactions

The firm was recently selected by IAM Magazine as one of the top 3 highly recommended Israeli firms in the field of licensing, stating that “Horn & Co is in its element when commercialising intellectual property; its finely honed business instincts ensure that it can identify the best routes to maximize portfolio value”. With a thorough understanding of the complexities and requirements of technology-based, long-haul development companies, the firm represents clients in all aspects of strategic transactions. Recent transactions included dozens of agreements with technology transfer companies of the world’s leading academic institutions, and the representation of Zebra Medical Vision Ltd. in a software License Agreement with Intermountain Healthcare.

Mergers & Acquisitions

The firm has a substantial track-record in representation of purchasers and targets in private and public M&A transactions, and is widely experienced in private and public mergers including the involvement and advice in reverse mergers, mergers into publicly traded shells, asset purchases and share acquisitions. Some recent examples are the representation of IOptima Ltd. and its shareholders in a multi-stage acquisition transaction with an aggregate deal value of up to approximately $50 million; representation of Eloxx Pharmaceuticals Ltd. in a $38 million financing round and simultaneous entering into an agreement for an acquisition transaction with Sevion Therapeutics, Inc. and the representation of cCam Biotherapeutics Ltd. in its sale to Merck & Co. Inc.

Regulation

Horn & Co. regularly advises international and Israeli companies with respect to their relationships with the Israel Innovation Authority, and assists in structuring both local and cross-borders technology transactions so to adequately conform to applicable regulations and legal requirements. The firm has advised several multinational companies with respect to the incorporation and setting up of businesses in Israel, as well as their relationships with the various governmental branches. Horn & Co. is the Israeli member of TRACE (www.traceinternational.org). 

Securities and Capital Markets

The firm has special experience in registration and issuance of securities of technology companies on US and Israeli securities exchanges, including IPOs, initial coin offering, follow-on offerings and PIPEs and is ranked as such in international publications. Recent transactions included Initiation and acting as Israeli counsel of the first submission of a prospectus to the SEC covering security to tokens. acting as Israeli counsel to Protalix BioTherapeutics, Inc. (NYSE: PLX) in a $54.1 million private notes exchange agreement, and a $22.5 million private placement of the company’s Secured Convertible Notes, the representation of Vascular Biogenics Ltd. in as a series of follow-on offerings on NASDAQ with an aggregate value of over $60 million, and the representation of two Israeli publicly traded companies in NASDAQ offerings.

Venture Capital

Horn & Co. advises companies, founders, government funded incubators, private investors and venture capital funds with respect to their full range of finance transactions, including seed rounds, venture capital funding, venture lending, strategic partner investments and mergers and acquisitions. Our close acquaintance with both company and investor needs and limitations further enables us to provide a unique view and expertise to transactions. We have advised on the formation of many funds, most recently Pontifax 4 (2014) and Pontifax 5 (2018), and regularly advise such funds with respect to their relationships with their limited partners. We represent funds in their initial and investments and continued involvement with portfolio companies.

You may also like

  • Humans at the Center of Things

    Humans at the Center of Things

  • Construction & Real Estate Sector

    In 2015-2016, several regulatory steps were taken by the government and the banks in order to affect the industry’s supply and demand. For example, demand-curtailing steps were taken aimed both at young couples (an increase of the mortgages interest rates by the banks) and at investors (governmental increase of investment apartments purchasing tax and taxation of third apartments). From the supply aspect – the “Mehir La’Mishtaken” (government price-capped) program was expanded, and the marketing of tens of thousands of reduced-price apartments for eligible candidates has begun.

    Construction & Real Estate Sector